Taiho Oncology Submits New Drug Application To The FDA for Treatment of Refractory Metastatic Colorectal Cancer
Taiho Oncology, Inc. has finalized its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for its proprietary TAS-102 (trifluridine and tipiracil hydrochloride) for the treatment ... Read more